DWTX Dogwood Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1818844 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY34.1%
TTM EPS YoY140.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-70.5%
ROA-30.0%
ROIC (approx.)-78.2%
Asset turnover—
Leverage & solvency
Liabilities / assets15.2%
Debt / equity0.00x
Current ratio2.78x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $21.87M | $3.53M | $1.73M | $8.07M | $10.80M |
| SG&A expense | $6.10M | $8.70M | $3.72M | $4.25M | $4.85M |
| Operating income | -$27.97M | -$12.23M | -$5.45M | -$12.32M | -$15.64M |
| Pretax income | -$34.04M | -$12.35M | -$5.30M | -$12.25M | -$15.96M |
| Income tax | $221,096 | -$503 | — | — | — |
| Net income | -$34.26M | -$12.35M | -$5.30M | -$12.25M | -$15.96M |
| EBITDA | -$27.97M | -$12.22M | — | — | — |
| EPS (basic) | -7.13 | -12.52 | -7.05 | -1.11 | -1.92 |
| EPS (diluted) | -7.13 | -12.52 | -7.05 | -1.11 | -1.92 |
| Weighted avg. shares (diluted) | 4.98M | 1.03M | 751,071 | 11.07M | 8.33M |
| Banking | |||||
| Net interest income | — | — | $150,904 | $67,475 | $5,672 |
| Balance sheet | |||||
| Cash & equivalents | $6.52M | $14.85M | $3.32M | $7.03M | $14.01M |
| Current assets | $8.43M | $16.54M | $4.17M | $8.37M | $15.78M |
| PP&E, net | $12,754 | $16,811 | — | — | — |
| Goodwill | $12.40M | $11.81M | — | — | — |
| Intangibles | $68.99M | $65.71M | — | — | — |
| Total assets | $90.17M | $94.31M | $4.17M | $8.37M | $15.78M |
| Current liabilities | $3.06M | $3.18M | $358,548 | $1.04M | $1.28M |
| Total liabilities | $15.27M | $30.03M | $358,548 | $1.04M | $1.28M |
| Shareholders' equity | $74.90M | -$10.12M | $3.81M | $7.33M | $14.50M |
| Shares outstanding | 29.74M | 1.33M | 770,317 | 18.33M | 8.33M |
| Cash flow statement | |||||
| Operating cash flow | -$15.62M | -$8.79M | -$4.87M | -$11.47M | -$15.69M |
| Investing cash flow | — | $3.76M | — | — | — |
| Financing cash flow | $7.28M | $16.70M | $1.16M | $4.49M | -$97,604 |
| Depreciation & amortization | $2,063 | $12,177 | — | — | — |
| Stock-based compensation | $355,642 | $476,021 | $619,972 | $582,659 | $322,881 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.